Dimerix Ltd represents a set of values and a corporate philosophy that emphasize innovation, scientific excellence, and patient-centered healthcare solutions. With a focus on developing novel therapies for unmet medical needs, Dimerix is committed to enhancing the lives and treatment options for patients. Through collaboration, research, and the application of advanced technology, the company strives to deliver high-quality pharmaceutical products and make a positive impact in the healthcare industry. Dimerix Ltd's dedication to scientific rigor, customer satisfaction, and improving patient outcomes sets a strong foundation for its growth and success in the market.

Dimerix Ltd is primarily present in Australia.

Dimerix Ltd has achieved several significant milestones. The company successfully completed its Phase 2 clinical trials for DMX-200, its lead drug candidate. Dimerix also received Orphan Drug Designation from the FDA for DMX-200 in primary Focal Segmental Glomerulosclerosis (FSGS) patients. Additionally, the company secured important partnerships and collaborations with renowned organizations and experts in the field. Dimerix's commitment to innovation and clinical advancement has positioned the company as a leader in the biopharmaceutical industry.

Dimerix Ltd is a renowned Australian biopharmaceutical company that specializes in the development and commercialization of innovative therapies. Established in [year], Dimerix has a strong history of cutting-edge research and collaboration with leading scientific institutions. The company's primary focus lies in developing novel treatments for unmet medical needs, particularly in the field of kidney disease and cancers. Dimerix's expertise lies in its proprietary drug development platform, enabling the identification and optimization of potential drug candidates. With a dedicated team of experts, Dimerix is committed to advancing scientific breakthroughs and improving the lives of patients worldwide.

The main competitors of Dimerix Ltd in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services as Dimerix Ltd. However, Dimerix Ltd stands out due to its unique offerings and strong market presence. Despite facing competition, Dimerix Ltd continues to solidify its position as a market leader through innovation, strategic partnerships, and consistent growth.

Dimerix Ltd is primarily active in the biotechnology and pharmaceutical industries.

Dimerix Ltd is an Australian-based biopharmaceutical company specializing in the development of innovative therapies. The business model of Dimerix revolves around identifying and advancing novel drug candidates that target diseases with high unmet medical needs. By utilizing their proprietary technology platforms and expertise in drug discovery, Dimerix aims to provide effective treatments for patients suffering from conditions such as chronic kidney disease and cancer. Through strategic collaborations and partnerships, Dimerix strives to facilitate the development and commercialization of their potential therapies, ultimately improving patients' lives and driving value for their stakeholders.

Dimerix P/E-luku on −23,05.

Dimerix KUV on 51,65.

AlleAktien Laatuscore Dimerix on 7/10.

Dimerix liikevaihto on 5,91 milj. AUD.

Dimerix voitto on −13,25 milj. AUD.

Dimerix Ltd is a global biotech company specialized in identifying and developing new therapeutics for serious diseases. The company utilizes an innovative strategy that uses G-Protein Coupled Receptors (GPCRs) as targets for drug development. Their business model focuses on developing both their own drug candidates and customized solutions for clients. They employ various platform technologies and tools to analyze the functioning of GPCRs and their interaction with other proteins in signaling pathways. Dimerix offers a range of molecular tools that can be used for identifying new drug candidates and validating targets. Their main products include specialized screening kits that modulate the GPCR signaling pathway and facilitate drug identification. These kits are sold to pharmaceutical and biotech companies as well as academic research institutions. Dimerix also provides customized services tailored to the needs of clients, ranging from identifying potential drug candidates to evaluating the efficacy and toxicity of existing drug candidates. These customized services are primarily sold to pharmaceutical and biotech companies involved in their own drug development. Another important aspect of Dimerix's business model is collaboration with other companies and research institutions. Dimerix works closely with partners to develop new drug candidates and target validation solutions. An example of such collaboration is the partnership with pharmaceutical company Merck KGaA to develop new immuno-oncology drugs. Dimerix has a strong financial position and has successfully completed numerous financing rounds to expand its product range and services. The company also has a strong intellectual property position secured through patents and licensing agreements. In summary, Dimerix's business model is focused on identifying and developing novel drugs for serious diseases. The company utilizes innovative platform technologies and tools to analyze GPCR signaling pathways and identify new targets. Dimerix offers both their own products and customized services to support clients in drug development. With close collaboration with partners and a strong financial position, the company is well positioned to advance its mission and provide innovative solutions for patients.

Dimerix maksaa osinkoa 0 AUD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Dimerix:lle tai yhtiö ei maksa osinkoa.

Dimerix:n ISIN on AU000000DXB7.

Dimerix:n tunnus on DXB.AX.

Viimeisen 12 kuukauden aikana Dimerix maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Dimerix maksanee ennusteiden mukaan 0 AUD osingon.

Dimerix:n tämänhetkinen osinkotuotto on .

Dimerix maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Dimerix maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 AUD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Dimerix kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Dimerix osingon 29.10.1999, jonka suuruus on 0,008 AUD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 24.9.1999.

Viimeisin osinko maksettiin 29.10.1999.

Vuonna 2024 Dimerix maksoi 0 AUD osinkoina.

Dimerix:n osingot maksetaan AUDssa.